evidencegaps
Cochrane · systematic review · CD013079

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis

Frost, F, Shaw, M, Nazareth, D · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library

Cystic Fibrosis and Genetic Disorders2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Summary of findings ‐ AZLI compared with placebo for chronic Burkholderia cepacia complex infection in people with CF

Population: adults and children with CF
5 questions
OutcomeEffectEvidenceStatus / GRADE
Relative change in FEV1% predicted
Summary of findings ‐ AZLI vs placebo
no estimate extracted1 study · 99 participantsModerate
Downgraded: imprecision
Days to next exacerbation
Summary of findings ‐ AZLI vs placebo
no estimate extracted1 study · 100 participantsModerate
Downgraded: imprecision
Participants hospitalised for respiratory exacerbation
Summary of findings ‐ AZLI vs placebo
RR 0.88 [0.53, 1.45]1 study · 100 participantsModerate
Downgraded: imprecision
Any AEs
Summary of findings ‐ AZLI vs placebo
RR 1.08 [0.98, 1.19]1 study · 100 participantsModerate
Downgraded: imprecision
Mortality
Summary of findings ‐ AZLI vs placebo
RR 5.41 [0.27, 109.87]1 study · 100 participantsModerate
Downgraded: imprecision